Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Bufei Yishen Granule, Randomized Controlled Trial
Brief summary
This study aims to establish the treatment scheme of Bufei Yishen granule for GOLD stage 3 or 4 chronic obstructive pulmonary disease (COPD), reducing acute exacerbation, improving exercise capacity and forming high quality evidence.
Detailed description
COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. Frequent acute exacerbation and exercise limitation broadly exist in COPD patients, especially those in GOLD stage 3 or 4. Although appropriate pharmacological therapies have been proven to be effective in COPD management, however, many gaps are still to be filled. For example, the adverse effects of pharmacologic therapies can never be ignored. The investigator's previous studies suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 3 or 4 COPD. This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Yishen granule on reducing acute exacerbation in GOLD stage 3 or 4 COPD subjects. After a 14-day run-in period, 348 subjects will be randomly assigned to treatment group or control group for 52-week treatment. The primary outcomes are frequency and duration of acute exacerbation. The secondary outcomes include mortality, pulmonary function, clinical symptoms, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.
Interventions
DRUGBufei Yishen granule
Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
DRUGPlacebo Bufei Yishen granule
Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
DRUGTiotropium Bromide Powder for Inhalation
Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Sponsors
ShuGuang Hospital
Henan University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A confirmed diagnosis of GOLD stage 3 or 4 COPD. * Syndrome differentiation meets criteria of Qi deficiency of the lung and spleen syndrome, Qi deficiency of the lung and kidney syndrome or Qi and Yin deficiency of the lung and kidney syndrome. * Age ranges from 40 years to 80 years. * With informed consent signed.
Exclusion criteria
* Pregnant and lactating women. * Patients with severe cardiovascular and cerebrovascular diseases. * Patients with severe liver and kidney diseases. * Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, chronic respiratory failure or other severe respiratory diseases. * Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years. * Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases. * Patients with severe cognitive and psychiatric disorders. * Patients with diabetes. * Patients who were administered oral glucocorticoids in the past 4 weeks. * Patients who have participated in other clinical studies in the past 4 weeks. * People who are allergic to the treatment drugs. * Patients who have experienced one or more acute exacerbation in the past 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of acute exacerbation | Up to week 52. | Frequency of acute exacerbation will be recorded. |
| Duration of acute exacerbation | Up to week 52. | Duration of acute exacerbation will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical symptom assessment questionnaire | Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52. | Clinical symptom assessment questionnaire of COPD will be used to assess symptom. |
| 6MWD | Change from baseline 6MWD at week 13, 26, 39 and 52. | Six-minute walk distance (6MWD) will be conducted to assess exercise capacity |
| CAT | Change from baseline CAT scores at week 13, 26, 39 and 52. | COPD assessment test (CAT) will be used to assess quality of life. |
| Mortality | Up to week 52. | The mortality will be calculated. |
| mCOPD-PRO | Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52. | The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status. |
| mESQ-COPD | Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52. | The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction. |
| SF-36 | Change from baseline SF-36 scores at week 13, 26, 39 and 52. | The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life. |
| FEV1 | Change from baseline FEV1 at week 26 and 52. | Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function. |
Countries
China
Contacts
Primary ContactXueqing Yu, Doctor
Outcome results
None listed